Palisade Bio

Palisade Bio Net Debt per Share

The Net Debt per Share of Palisade Bio (PALI) as of Nov 19, 2026 is -94.12 USD. In the previous year, Net Debt per Share was -6.81 USD — a change of 1,281.21% (lower).

Net Debt per Share

-94.12USD

YoY

1,281.21%

Last updated:

Net Debt per Share of Palisade Bio is 2025 -94.12 USD. Net Debt per Share of Palisade Bio was 2024 -6.81 USD. It decreases by 1,281.21% lower compared to the previous year.

The Palisade Bio Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
-0.53 USD
Jan 1, 2019
-3.41 USD
Jan 1, 2020
0.49 USD
Jan 1, 2021
-7.27 USD
Jan 1, 2022
-8.46 USD
Jan 1, 2023
-8.52 USD
Jan 1, 2024
-6.81 USD
Jan 1, 2025
-94.12 USD
The Palisade Bio Net Debt per Share history
YEARNet Debt per ShareYoY
-94.12USD+1,281.21%
-6.81USD-19.99%
-8.52USD+0.70%
-8.46USD+16.35%
-7.27USD-1,587.86%
0.49USD-114.34%
-3.41USD+544.28%
-0.53USD-95.46%
-11.64USD+282.92%
-3.04USD-77.02%
-13.23USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Palisade Bio Stock analysis

What does Palisade Bio do? Palisade Bio, Inc. develops oral therapies for gastrointestinal complications caused by post-operative digestive enzyme damage. The company focuses on LB1148, an oral liquid formulation containing tranexamic acid (TXA), polyethylene glycol, carbohydrates, and electrolytes, designed to prevent enzyme leakage into the peritoneal cavity during high-risk surgeries. LB1148 is administered before surgeries to protect the intestinal epithelial barrier. The company's lead product targets acute and chronic conditions resulting from digestive enzyme damage, with no other products or revenue streams mentioned. Palisade Bio, Inc. is a biopharmaceutical company headquartered in Carlsbad, California, employing 12 full-time employees. It went public via IPO on December 20, 2006, but does not generate revenue from product sales as it is in the development phase. The company's business model relies on developing therapies like LB1148 for surgical patients, with no indication of partnerships, licensing deals, or other revenue sources beyond potential future product sales after regulatory approval. The lead therapeutic candidate LB1148 is formulated as an aqueous solution for oral (enteral) administration. The company's approach is based on the discovery that intestinal epithelial barrier damage leads to digestive enzyme leakage, causing tissue damage and inflammation. No other products, brands, or revenue streams are referenced in the business description, and the company does not sell any products at this stage. Palisade Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Palisade Bio stock

Net Debt per Share of Palisade Bio is -94.12 USD in 2025.

Net Debt per Share of Palisade Bio changed from -6.81 USD to -94.12 USD, representing a 1,281.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Palisade Bio since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Palisade Bio

All Key Metrics — Palisade Bio